0
No votes yet
Advanced Practice Nursing Issues

The Wave of the Future: Genetic Profiling in Treatment Selection

Jennifer C. Ewing
CJON 2014, 18(6), 717-718 DOI: 10.1188/14.CJON.717-718

Chemotherapy treatment recommendations traditionally have been based on the anatomic site of origin and the histology of the tumor. More recently, treatment options are transitioning to targeted therapies, in which drug selection is based on mutations present in an individual tumor. Genomic testing is a developing area that involves testing tumors to determine their molecular or genetic characteristics, then matching those characteristics to treatments that specifically target them.

References 

Foundation Medicine, Inc. (n.d.) <i>FoundationOne® experience on 13,000+ patients.</i> Retrieved from <a target="_blank" href='http://www.foundationone.com/docs/FoundationOne%20Experience%2013k+.pdf'...

Frampton, G. M., Fichtenholz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., … Yelensky, R. (2013). Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. <i>Nature Biotechnology, 11</i>, 1023-1031. doi:10.1038/nbt.2696

Lennerz, J. K., Kwak, E. L., Ackerman, A., Michael, M., Fox, S. B., Bergethon, K., … Iafrate, A. J. (2011). <i>MET</i> amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. <i>Journal of Clinical Oncology, 29</i>, 4803-4310. doi:10.1200/JCO.2011.35.4928

Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., … Salgia, R. (2008). Expression and mutational analysis of <i>MET</i> in human solid cancers. <i>Genes, Chromosomes and Cancer, 47</i>, 1025-1037. doi:10.1002/gcc.20604

Ou, S. H., Kwak, E. L., Siwak-Tapp, C., Dy, J., Bergethon, K., Clark, J. W., … Iafrate, A. J. (2011). Activity of crizotinib (PF02341066), a dual mesenchymalepithelial transition (<i>MET</i>) and anaplastic lymphoma kinase (<i>ALK</i>) inhibitor, in a non-small cell lung cancer patient with de novo <i>MET</i> amplification. <i>Journal of Thoracic Oncology, 6</i>, 942-946. doi:10.1097.JTO.0b013e31821528d3

Stump, T. K., Eghan, N., Egleston, B. L., Hamilton, O., Pirollo, M., Schwartz, J. S., … Wong, Y. N. (2013). Cost concerns of patients with cancer. <i>Journal of Oncology Practice, 9</i>, 251-257. doi:10.1200/JOP.2013.000929